The £3m Price Tag on Hope: Inside the Sanfilippo Crisis

Tate McDaid is five. He lives in Swansea, Wales. He has Sanfilippo Syndrome. This is a rare form of childhood dementia that eats away at the brain.

It takes walking. It takes eating. It takes the ability to recognize a parent. There are no other treatments.

There is only the new drug, Fayrvi, and a bill that makes the local hospital’s entire annual budget look like pocket money. His mother, Tammy, has been raising funds for months. She has gathered over £160,000. It feels like a lifetime of work. It is, however, barely 5% of what is needed.

The gap between that amount and the final cost is £2.95 million. In a world where a single course of gene therapy can cost more than a house, we are forced to ask: who is this medicine actually for?

The Medicine That Cannot Cross the Border

The approval happened in September. It was supposed to be a moment of pure relief. For Tammy, that relief lasted exactly one day. She read about the price.

She called the developers. She asked a simple question. How much does it cost for a family in the UK without American insurance? The answer was evasive.

“There is not a single estimate we can provide,” Ultragenyx, the maker of the drug, told reporters. They said the cost depends on individual medical needs. They said it depends on the treating institution. It is a non-answer that leaves families stranded.

The US pricing model assumes a complex web of insurance negotiations. The UK has none of that structure for this specific experimental access. The drug exists, but it is locked in a vault with a price on the door that the National Health Service cannot currently pay.

Health officials in Wales are now in talks with US counterparts. They are trying to find a pathway. A backdoor. A waiver.

Anything. The clock is ticking because Tate turns six this month. After age five, the progression of the disease accelerates rapidly. Every month of negotiation is a month of lost neural pathways.

That is a harder sell than it sounds. The science is sound, but the logistics are a nightmare.

Why the Price Is Stuck at $4 Million

Gene therapy is expensive. This is not news. The first successful gene therapies for rare diseases have set the bar high. We are talking about engineering the human genome inside the body.

That kind of technology demands a return on investment. The companies need to track down not just the lost revenue from development, but the future pipeline as well.

But is $3.95 million a barrier or a profit margin? That is the question haunting families. Past events, like the $2.1 million price tag for Zolgensma, showed that insurers eventually folded. They paid.

But that was in the US. In the UK, the NHS cannot absorb a single case of this magnitude without collapsing the system for everyone else. It is a unique economic puzzle with no clean solution.

Pharmaceutical executives often talk about “value-based pricing.” They argue that if the treatment saves a life, it is worth it. But value is subjective. It is distinct from affordability. For a rare disease with 100 patients in a country, the math never makes sense for a public payer. We are stuck between the cold reality of corporate balance sheets and the hot reality of a child’s failing brain.

What This Means for India

Let’s talk about India, because this story is not just a Western one. India has a large population of Indians living abroad, and many have family back home. If a child in Mumbai has Sanfilippo Syndrome, the cost is even more inaccessible. A dollar in India is worth far less in purchasing power.

This treatment would cost upwards of ₹300 crore for a single child. That is not a personal tragedy; it is a national impossibility.

However, the India angle is sharper than it appears. India is a global hub for biological manufacturing. We produce a significant amount of the world’s vaccines and biologics. If the technology for gene delivery can be localized, the cost could drop dramatically.

But local production requires regulatory approval and manufacturing scale that does not exist yet for this specific drug. Until then, Indian families face the same wall as the British ones: they must travel, or they must wait for a miracle that may never come. The disconnect between global medical breakthroughs and local affordability is widening, and Indian policy-makers are silent on how to bridge it.

The Race Against the Clock

Tate is six now. He does not speak. He has never spoken. But he walks.

He runs. He is what Tammy calls “the happiest little man.” That mobility is everything. It is the last thing the disease has not taken. If the treatment works, it slows the decline.

It buys time. Months, maybe years, of continued ability. That is what she is fighting for.

The urgency is palpable. The older the patient, the less effective the treatment becomes. The brain has already suffered damage. You cannot unscramble an egg.

You can only try to stop the heat. The pharmaceutical company understands this. They say they are pursuing a global strategy. But a strategy is not a plan.

A plan has dates. A plan has money. Right now, there is only hope and a very small pile of coins raised from hundreds of small donors.

Nobody in the room looked convinced when the initial price was announced. The reaction was universal: shock. Then silence. Then the grinding work of fundraising.

It is a battle of time, and time is running out. The medication is real. The need is real. The funding is the only variable left to solve.

And it is a huge one. The next move belongs to the governments. Wales is asking the US for a pricing waiver. This is unusual. It is unprecedented.

The Next Step: Access or Appeal

It is a diplomatic request for a discount on a life-saving drug. The US has done this for other rare diseases. It could happen here. But it is not guaranteed.

If the waiver is denied, the options narrow. They could try private insurance in the US, which will likely reject a pre-existing condition of this scale. They could seek emergency compassionate use, which is denied more often than granted. Or they could rely on the public.

The goal is £2.95 million. They have a long way to go. The next vote, or decision, comes when the US regulators respond to the Welsh health department’s inquiry. That response could come in days or months.

Every day that passes is a day Tate’s world shrinks by another inch. It is a terrifying wait.

Frequently Asked Questions

What is Sanfilippo Syndrome?

It is a rare genetic disorder that causes dementia in children. It is also known as Mucopolysaccharidosis type III. It leads to the breakdown of brain cells, resulting in a loss of speech, mobility, and cognitive function. There is currently no cure other than the new gene therapy.

How much does the treatment cost?

The US price for one course is $3.95 million. This is approximately £2.95 million or €3.6 million. The cost is for a one-time infusion that is meant to last for the life of the patient. It is one of the most expensive drugs ever approved.

Can UK families get the treatment?

Not yet. The drug is not approved by UK regulators like the MHRA. Families would need to travel to the US to receive it. The NHS does not currently cover the cost of such experimental overseas treatments without a specific regulatory pathway, which is under negotiation.

Is there a cheaper alternative?

There is no confirmed cheaper alternative right now. Some experimental methods exist, like enzyme replacement therapy, but they do not cross the blood-brain barrier effectively. Gene therapy is the only option shown to slow disease progression significantly. The cost may drop if the drug is approved in other markets and competition enters the space.

Source: BBC Health